Eloxx Pharmaceuticals is a biopharmaceutical company focused on ribosome modulation for rare premature stop codon diseases and has a lead drug in a Phase 2 clinical trial. The company also develops preclinical programs and earlier discovery stage programs in oncology. Eloxx Pharmaceuticals was founded in 2013 and is based in Watertown, Massachusetts.